Cancer Imaging最新文献

{"title":"[¹⁸F]PSMA-1007 and [¹⁸F]FDG PET/CT in patients with metastatic triple-negative breast cancer: a prospective head-to-head comparison and assessment of PSMA-targeted radioligand therapy applicability.","authors":"Tatiana Nikolaevna Lazutina, Aleksandr Igorevich Khalimon, Soslan Rolanovich Urtaev, Malika Maratovna Khodzhibekova, Daria Yurevna Khodakova, Gulnara Faridovna Khamadeeva, Anastasia Igorevna Nikiforuk, Irina Valentinovna Pylova, Aleksei Victorovich Leontev, Andrey Dmitrievich Kaprin","doi":"10.1186/s40644-026-01028-6","DOIUrl":"10.1186/s40644-026-01028-6","url":null,"abstract":"<p><strong>Background: </strong>Triple-negative breast cancer (TNBC) is an aggressive molecular subtype of breast cancer with limited treatment approaches. Prostate-specific membrane antigen (PSMA), widely applied as a target for molecular imaging and radioligand therapy of prostate cancer, demonstrates the highest expression in TNBC across all molecular subtypes of breast cancer, and represents a promising target for imaging and treatment of TNBC patients.</p><p><strong>Methods: </strong>This prospective study included 20 patients with metastatic TNBC who underwent both [¹⁸F]PSMA-1007 and [¹⁸F]FDG PET/CT. Qualitative and quantitative image analysis was performed to determine the uptake predominance of one of the tracers and the added value of the diagnostic CT, as well as to assess the potential applicability of PSMA-targeted radioligand therapy (PSMA-RLT).</p><p><strong>Results: </strong>A total of 229 lesions were identified using both [¹⁸F]PSMA-1007 and [¹⁸F]FDG PET/CT. Concordant and discordant lesions were observed for both tracers, with a greater number of discordant lesions identified by [¹⁸F]PSMA-1007. [¹⁸F]FDG demonstrated higher uptake in TNBC lesions. An exception was observed in lung lesions, where no significant difference was found between tracers. The application of diagnostic CT revealed additional TNBC lesions that were not identified by PET, for each tracer. None of the patients demonstrated a [¹⁸F]PSMA-1007 uptake level sufficient for potential PSMA-RLT application when a lesional SUV-based threshold was used.</p><p><strong>Conclusion: </strong>Despite detectable [¹⁸F]PSMA-1007 uptake in TNBC lesions, [¹⁸F]FDG uptake was generally higher. Furthermore, the diagnostic CT can identify additional PET-negative lesions. Although PSMA expression is confirmed in TNBC, it may be insufficient to provide potential benefit from PSMA-RLT for this patient group.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13217786/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147653724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal change in skeletal muscle index as a predictor of recurrence for patients with locally advanced colorectal malignancy: a retrospective cohort study.","authors":"Noah B Manz, Jordan Reed, Christopher D Kanner, Jeremy A Dressler","doi":"10.1186/s40644-026-01025-9","DOIUrl":"10.1186/s40644-026-01025-9","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer remains a leading cause of cancer-related morbidity and mortality with stage III disease carrying a substantial risk of recurrence despite curative resection. Accurate risk stratification is essential to optimize surveillance and guide adjuvant therapy. Traditional risk models rely heavily on pathologic features, but recent studies suggest that body composition metrics, particularly imaging-based assessments of skeletal muscle mass, may offer additional prognostic value. The skeletal muscle index (SMI), derived from routine CT imaging, has emerged as a promising surrogate marker of frailty. However, the relationship between temporal changes in SMI and cancer recurrence remains poorly understood.</p><p><strong>Methods: </strong>A retrospective cohort study was performed using single-institution data from over 500 patients who underwent resection for stage III colorectal malignancy. SMI at diagnosis (SMI_dx) was measured using staging CT imaging and follow-up measurements (SMI_fu) were obtained at the most recent scan prior to recurrence to capture changes preceding radiologic evidence of disease. Patients were paired using propensity score matching and temporal changes in SMI were evaluated using conditional logistic regressions. Receiver operating characteristics and decision curve analysis were performed to determine whether change in SMI can stratify patients into meaningful risk groups to guide surveillance.</p><p><strong>Results: </strong>A decrease in SMI was independently associated with increased risk of disease recurrence with an odds ratio of 2.23 per 10% decline (95% CI: 1.15-4.35, p = 0.018). Baseline muscle status was not associated with recurrence (OR 1.01 per cm²/m², 95% CI: 0.97-1.05, p = 0.585). The optimal risk stratification threshold was θ = 2.11%, (θ = SMI_fu / SMI_dx - 1) with a sensitivity of 90% and specificity of 60%. Decision curve analysis showed net clinical benefit over a wide range of thresholds, θ = ±11%. These results were reproduced in an internally validated cohort.</p><p><strong>Conclusions: </strong>Postoperative decline in skeletal muscle index is a significant, independent predictor of colorectal cancer recurrence. Clinically relevant risk stratification thresholds have been proposed and support the conclusion that longitudinal monitoring of SMI may have value to escalate surveillance intensity rather than being a passive prognostic marker. Future studies should focus on validating these thresholds in large, multi-center cohorts.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13154471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147632525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of real-time shear wave elastography combined with serum thyroglobulin in thyroid cancer.","authors":"Yunyan Fang, Biaohu Liu, Huijun Feng, Jing Hu","doi":"10.1186/s40644-026-01027-7","DOIUrl":"10.1186/s40644-026-01027-7","url":null,"abstract":"<p><p>OBJECTIVE: To evaluate the diagnostic value of combining real-time shear wave elastography (SWE) with serum thyroglobulin (Tg) in thyroid cancer (TC) and explore its potential for assessing tumor aggressiveness. METHODS: This retrospective study included 124 patients with TC and 62 with benign thyroid lesions (January 2024–August 2025). Malignant cases were classified as invasive (n = 78) or non-invasive (n = 46) based on capsular involvement, vascular invasion, or lymph node metastasis. All patients underwent SWE and Tg testing. SWE parameters—maximum (Emax), mean (Emean), minimum (Emin) Young’s modulus—and Tg levels were compared. ROC analysis assessed diagnostic performance, while Spearman correlation examined relationships between SWE and Tg. RESULTS: All malignant cases were papillary thyroid carcinoma. Malignant cases had higher SWE parameters and Tg than benign cases (P < 0.05). Invasive tumors showed higher Emax, Emean, and Tg than non-invasive tumors (P < 0.05). The combined SWE–Tg model AUC for malignancy was 0.844; for aggressiveness, 0.744. Tg correlated positively with SWE parameters (P < 0.001). CONCLUSION: Combining SWE with Tg improved discrimination between TC and benign thyroid nodules in this cohort and may provide auxiliary value for preoperative assessment of invasive features. </p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13174007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147615925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CT predictors of visceral pleural invasion in subsolid nodular pulmonary adenocarcinoma: differences between direct and indirect tumor-pleura contact.","authors":"Yun Wang, Deng Lyu, Xiaoli Deng, Lei Hu, Junhong Wu, Xiuxiu Zhou, Yi Xiao, Li Fan, Shiyuan Liu","doi":"10.1186/s40644-026-01029-5","DOIUrl":"10.1186/s40644-026-01029-5","url":null,"abstract":"<p><p>BACKGROUND: Preoperative accurate prediction of visceral pleural invasion (VPI) in subsolid nodular pulmonary adenocarcinoma (PA) can provide guidance for the surgical method of early lung cancer. The aim of this study is to explore the value of CT features in predicting VPI in clinical stage IA subsolid nodular peripheral PA with contact with the pleura. METHODS: A total of 464 patients across three hospitals were retrospectively analyzed. The internal dataset (n = 363) was divided into training cohort (n = 244) and internal validation cohort (n = 119) based on examination time, using a 7:3 ratio. Patients were categorized into VPI-positive and VPI-negative groups according to the pathological diagnosis. The CT features were analyzed, including pleural end characteristics, tumor signs, and tumor-pleural features. Multivariate logistic regression analyses were performed to screen the optimal combination of variables for predicting VPI. Based on these variables, a predictive model and corresponding nomogram were developed, and their predictive performance was evaluated using external validation cohort (n = 101). According to the type of tumor-pleural contact, it was divided into indirect and direct contact types. Subgroup analyses were subsequently performed for each category to identify CT features indicative of VPI. RESULTS: Multivariable logistic regression analysis identified the optimal combination of predictor variables, including solid component diameter, tumor-pleura relationship, vacuole sign, vascular convergence sign, and soft tissue density shadow of pleural end. Among them, solid component diameter (OR = 1.17), the Type III classification of the tumor-pleura relationship (OR = 7.43), Type IV (OR = 37.22), and Type V (OR = 13.62) were independent risk factors. The AUC values of the model for predicting VPI in three cohorts were 0.833, 0.781, and 0.796, respectively. Subgroup analysis further revealed that solid component diameter (OR = 1.12), Type IV tumor-pleura relationship (OR = 27.63), vascular convergence sign (OR = 10.68) and soft tissue density shadow of pleural end (OR = 10.48) were independent risk factors for indirect contact type, whereas solid component diameter (OR = 1.15), Type V tumor-pleura relationship (OR = 4.44), and solid component contact pleura (OR = 6.23) were independent risk factors for direct contact type. CONCLUSIONS: The model based on CT features demonstrated acceptable diagnostic efficacy in predicting VPI. The types of tumor-pleural contact are different, and there are differences in CT predictive variables. </p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13170325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147590239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of multimodal CEST, perfusion and diffusion MRI for predicting clinical outcome of patients with diffuse glioma following surgery at baseline before radiotherapy.","authors":"Nikolaus von Knebel Doeberitz, Petr Menshchikov, Florian Kroh, Laila König, Svenja Graß, Cora Bauspieß, Philip S Boyd, Sebastian Regnery, Thomas Zeyen, Stephen Schaumann, Ralf Floca, Daniel Hasson, Moritz Scherer, Martin Bendszus, Wolfgang Wick, Jürgen Debus, Peter Bachert, Mark E Ladd, Heinz-Peter Schlemmer, Andreas Korzowski, Daniel Paech","doi":"10.1186/s40644-026-01022-y","DOIUrl":"10.1186/s40644-026-01022-y","url":null,"abstract":"<p><p>BACKGROUND: To assess the predictive value of different chemical exchange saturation transfer (CEST) contrasts, i.e. of the amide proton transfer (APT), relayed nuclear Overhauser effect (rNOE), and semi-solid magnetization transfer (ssMT), as well as of clinical routine perfusion- and diffusion-weighted MRI, in terms of treatment outcome in patients with glioma following surgery at baseline before radiotherapy at 3 T. MATERIALS AND METHODS: From September 2018 to December 2022, 78 study participants (median age 62 years, 27/78 female) prospectively underwent CEST, diffusion, and perfusion imaging. CEST contrasts were reconstructed for the APT-weighted magnetization transfer ratio asymmetry (APTwasym), relaxation-compensated CEST metrics (MTRRexAPT, MTRRexNOE, MTRRexMT), and MTconst. Contrast-enhancing and whole tumor volumes were segmented on T2w-FLAIR and T1w images. Associations of mean contrast values with therapy response were tested using ROC analyses, while relationships with progression-free survival (PFS, median 6.04 months) and overall survival (OS, median 11.58 months), as well as added benefit compared to nCBV and ADC maps, were assessed using dichotomized Cox regression models. RESULTS: MTRRexAPT, MTRRexNOE, and MTRRexMT were associated with therapy response (AUC = 0.82, 0.81, 0.68; all p ≤ 0.03), PFS (HR = 2.92, 0.37, 3.40; all p ≤ 0.02), and OS (HR = 2.76, 0.63, 8.09; all p ≤ 0.05). MTconst was correlated with OS (HR = 5.52, p < 0.01), while APTwasym was linked to therapy response (AUC = 0.71, p = 0.02). MTRRexMT (χ² = 13.71, p < 0.01) and MTconst (χ² = 5.62, p = 0.018) provided each additional value to nCBV for OS prediction. CONCLUSION: Relaxation-compensated CEST imaging of the APT, rNOE, and ssMT, as well as conventional APTwasym showed ability to predict treatment outcome, whilst ssMT-weighted imaging provided added benefit for OS prediction in patients with diffuse glioma following surgery at baseline before radiotherapy at 3 T. </p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13151286/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147571988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surviving childhood cancer: the hidden threat of second malignancies.","authors":"Ritu Shah, Sireesha Yedururi, Rhea A Morani, Ishan Arora, Mary Austin, Nisha S Ramani, Cynthia E Herzog, Priya R Bhosale","doi":"10.1186/s40644-025-00933-6","DOIUrl":"10.1186/s40644-025-00933-6","url":null,"abstract":"<p><p>Despite improved cancer mortality rates, pediatric cancer survivors face significant challenges in the long term due to therapy-related complications. A critical complication is the development of second malignant neoplasms (SMNs), which account for nearly half of non-relapse deaths among long-term survivors. This imaging review touches upon various risk factors for SMN development such as chemotherapeutic drugs, radiation, hereditary syndromes, and hematopoietic stem cell transplantation. Common SMNs include leukemia, thyroid cancer, sarcoma, and breast carcinoma. Early detection through imaging and structured surveillance is critical for improving outcomes. Strategies to mitigate risks include dose modification, advanced radiation techniques, and comprehensive survivorship care. As the field of pediatric oncology progresses, a dual focus on optimizing primary cancer treatment and minimizing late effects like SMNs is paramount. Lifelong surveillance, tailored therapies, and interdisciplinary care models are essential for enhancing survivors' quality of life.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13147667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147526982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CT-based renal artery caliber change as a potential imaging marker of treatment response in renal cell carcinoma; an exploratory imaging study.","authors":"Himawari Asanuma, Teppei Okamoto, Tadashi Yoshizawa, Takuya Oishi, Tomoko Hamaya, Hirotake Kodama, Takuma Narita, Jotaro Mikami, Naoki Fujita, Tohru Yoneyama, Hayato Yamamoto, Atsushi Imai, Chikara Ohyama, Shingo Hatakeyama","doi":"10.1186/s40644-026-01023-x","DOIUrl":"10.1186/s40644-026-01023-x","url":null,"abstract":"<p><strong>Background: </strong>To evaluate whether treatment-induced changes in tumor-bearing renal artery caliber on contrast-enhanced CT are associated with pathological response and pathological downstaging after systemic therapy in locally advanced or metastatic renal cell carcinoma (RCC), and to explore the clinical relevance of this vascular parameter.</p><p><strong>Methods: </strong>We retrospectively analyzed 43 patients with locally advanced or metastatic RCC who underwent systemic therapy followed by nephrectomy. Renal artery inner diameter was measured on arterial-phase CT before and after treatment using curved planar reformation. Interobserver reproducibility of the measurement was excellent (intraclass correlation coefficient [ICC] = 0.992). A subset of 33 patients had adequate bilateral imaging for tumor-bearing versus contralateral comparison. Tumor size was measured as the longest axial diameter on contrast-enhanced CT, and tumor shrinkage was expressed as percentage change from baseline according to RECIST 1.1 measurement principles. Choi criteria incorporated tumor size and attenuation changes. Pathological response was defined as the proportion of treatment-induced necrosis and fibrosis. Associations between arterial caliber change, pathological response, and pathological downstaging were assessed. Multivariable regression analysis identified independent predictors of pathological response. Discriminative ability for downstaging was evaluated using receiver operating characteristic analysis.</p><p><strong>Results: </strong>At baseline, the tumor-bearing renal artery had a larger inner diameter than the contralateral artery. After systemic therapy, its diameter significantly decreased (6.35 to 5.65 mm, p < 0.001). In the paired subset (n = 33), significant reduction occurred only in tumor-bearing arteries. Percentage diameter reduction correlated with pathological response (r = 0.314, p = 0.040). Patients with pathological downstaging showed greater diameter reduction than those without downstaging (16.3% vs 6.83%, p = 0.021). Tumor size change based on RECIST principles and Choi criteria were not significantly associated with downstaging. Multivariable analysis confirmed renal artery diameter change rate as an independent predictor of pathological response. ROC analysis showed moderate discrimination for downstaging (AUC 0.71, 95% CI: 0.55-0.87).</p><p><strong>Conclusion: </strong>Reduction in tumor-bearing renal artery caliber was independently associated with pathological response and downstaging. This vascular parameter may complement conventional tumor-centered imaging criteria in selected patients.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13147648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147527061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[¹⁸F]AlF-NOTA-QHY-04 uptake in spleen before anti-tumor therapy may predict degree of myelosuppression for patients with small cell lung cancer.","authors":"Siyu Cai, Jingru Liu, Kai Cheng, Xinzhi Zhao, Shengnan Xu, Jinli Pei, Shijie Wang, Kunlong Zhao, Jinming Yu, Wanhu Li, Jie Liu","doi":"10.1186/s40644-026-01024-w","DOIUrl":"10.1186/s40644-026-01024-w","url":null,"abstract":"<p><p>BACKGROUND: The aim of this study was to assess the value of C-X-C motif chemokine receptor 4 (CXCR4) targeted positron emission tomography/computed tomography ([18F]AlF-NOTA-QHY-04 PET/CT) imaging in spleen for prediction of degree of myelosuppression in patients with small cell lung cancer (SCLC) before therapy. METHODS: 59 patients with SCLC underwent [18F]AlF-NOTA-QHY-04 PET/CT scanning before treatment. The maximum, mean, and peak standard uptake value (SUVmax, SUVmean, SUVpeak), metabolic tumor volume (MTV) and total lesion CXCR4 expression (TLC) of spleen at baseline were acquired. Chemotherapy-based treatment was administered for limited-stage and extensive-stage SCLC. The most severe degree of myelosuppression during the treatment was recorded. Patients were identified as mild and severe myelosuppression. Potential predictors were identified and validated through intergroup difference analysiis, ROC curve assessment, and ordinal regression analysis. RESULTS: Patients with severe myelosuppression exhibited significantly higher splenic uptake values (SUVmax, SUVmean, SUVpeak and TLC) compared to those with mild myelosuppression (all p < 0.05). Regions of interest (ROI) curve analysis identified that higher metabolic parameters, including SUVmax (AUC = 0.853, p < 0.0001), SUVmean (AUC = 0.885, p < 0.0001), SUVpeak (AUC = 0.821, p < 0.0001), TLC (AUC = 0.753, p = 0.0016), were significantly associated with more severe myelosuppression. Multivariate analysis identified SUVmax (p = 0.007) and age (p = 0.005) as significant independent predictors of treatment-related myelosuppression severity. CONCLUSIONS: Our findings suggest that baseline splenic [18F]AlF-NOTA-QHY-04 PET/CT parameters, particularly SUVmax, may help identify patients with small cell lung cancer who are at high risk of severe treatment-related myelosuppression, with older age serving as an additional clinical risk factor. </p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13147742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147527016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RADS classification systems for bone tumors: current status and where do we go from here?","authors":"Vu Pham Thao Vy, Shivani Ahlawat, Hillary W Garner, Jim S Wu","doi":"10.1186/s40644-026-01021-z","DOIUrl":"10.1186/s40644-026-01021-z","url":null,"abstract":"<p><p>The assessment and management of bone tumors can be challenging as there are numerous neoplastic and non-neoplastic lesions. It can be difficult to understand which lesions can be ignored and which lesions require treatment. To standardize the reporting and management of bone tumors, four bone-lesion related reporting and data systems (RADS) have been published since 2021. The Bone Tumor Imaging Reporting and Data System (BTI-RADS), Oncologic Tumor Reporting and Data System (OT-RADS), Society of Skeletal Radiology Bone Reporting and Data System (SSR Bone-RADS), and American College of Radiology Bone Reporting and Data System (ACR Bone-RADS) are based in part on Breast Imaging Reporting & Data System (BI-RADS). These bone-lesion related RADS aim to improve communication, simplify management, and improve diagnostic consistency by linking imaging features to specific risks and evidence-based action recommendations. Although these systems show high sensitivity for determination of malignancy and moderate consistency for intra-observer readings, their coexistence leads to fragmentation and a lack of a unifying system. This review will discuss the main features of these 4 RADS systems and discuss future directions.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13141412/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147519869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative parameters of dual-layer spectral CT for differentiating metastatic and non-metastatic lymph nodes in colorectal cancer.","authors":"Liyan Tang, Guoqing Liu, Xia Lv, Weicui Chen, Xian Liu","doi":"10.1186/s40644-026-01019-7","DOIUrl":"10.1186/s40644-026-01019-7","url":null,"abstract":"<p><p>BACKGROUND: To investigate the value of quantitative parameters obtained from dual layer spectrum CT (DLSCT) in distinguishing metastatic and non-metastatic lymph nodes in colorectal cancer (CRC). METHODS: This retrospective study enrolled 211 LNs from 66 CRC patients, including 78 metastatic LNs and 133 non-metastatic LNs. The morphological characteristics and quantitative DLSCT parameters of each identified lymph node were evaluated and compared. Univariate and multivariable logistic regression analyses were used to identify the independent factors for predicting LN metastasis. Receiver operating characteristic curve (ROC) and decision curve analysis (DCA) were employed to evaluate the diagnostic performance and clinical usefulness of the models. RESULTS: All morphological features differed between metastatic and non-metastatic LNs. Metastatic LNs showed significantly lower iodine concentration (IC) and normalized iodine concentration (NIC) in the arterial phase, while exhibiting higher effective atomic number (Zeff), normalized effective atomic number (nZeff) in the venous phase, and slope of the spectral Hounsfield unit curve (λHu) values in both phases. A positive correlation was found between λHu values of LNs and tumors in both the arterial and venous phases within the LN metastasis group. For differentiating metastatic and non-metastatic LNs, combined morphological features yielded an AUC of 0.695, with 66.7% sensitivity and 68.4% specificity, while a multivariate model incorporating DLSCT parameters improved this to 0.901, with 82.1% sensitivity and 87.2% specificity. The DeLong test and decision curve analysis (DCA) showed that quantitative multiparameter model offered better predictive performance and benefits for LN metastasis than the morphological features. CONCLUSION: Quantitative parameters from DLSCT provide significant value in distinguishing lymph node metastasis in colorectal cancer. </p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13127020/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147493694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}